Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Zai Lab LimitedNASDAQ: ZLAB

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 54.7%

Gross margin was 54.7% in Q2 FY2026, down 6.0 pp from a year earlier. On a trailing-twelve-month basis it was 56.5%, down 5.9 pp year over year. Over 3 fiscal years it narrowed by 7.1 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
54.7%-6.8 pp QoQ
Last fiscal yearDec 2025
58.5%-4.5 pp YoY
LTMJun 2026
56.5%-5.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.0 pp——
1 year-4.5 pp——
3 years-7.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
58.5%
Year-over-year change
-4.5pp

Gross Margin vs competitors

How ZLAB compares with its peers on the latest reported figures

  • ZLAB's LTM Jun 2026 gross margin of 56.5% is the 3rd highest of the 4 companies compared; the peer median is 76.4%.
  • Its year-over-year change of -5.9 pp is the highest of 3, against a peer median of -20.8 pp.
  • Over three fiscal years its change of -7.1 pp compares with a peer median of -0.7 pp.
ZLAB Competitors Peer median
Gross Margin for ZLAB and competitors
Company Period LTM level YoY 3-year change
ANLAdlai Nortye Ltd.LTM Jun 2024100.0% ——
AAPGAscentage Pharma Group InternationalFY202576.4% -20.6 pp-13.1 pp
ZLABZai Lab LimitedLTM Jun 202656.5% -5.9 pp-7.1 pp
HCMHUTCHMED (China) LimitedLTM Jun 20258.9% -20.9 pp+11.6 pp
Peer median (excluding ZLAB) 76.4%-20.8 pp-0.7 pp

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.